Dark Forest Capital Management LP Invests $1.24 Million in 10x Genomics, Inc. (NASDAQ:TXG)

Dark Forest Capital Management LP bought a new stake in 10x Genomics, Inc. (NASDAQ:TXG - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 86,504 shares of the company's stock, valued at approximately $1,242,000. Dark Forest Capital Management LP owned about 0.07% of 10x Genomics at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in TXG. Stifel Financial Corp raised its position in 10x Genomics by 56.2% in the third quarter. Stifel Financial Corp now owns 16,369 shares of the company's stock valued at $370,000 after purchasing an additional 5,890 shares during the period. Barclays PLC boosted its holdings in 10x Genomics by 11.7% in the third quarter. Barclays PLC now owns 602,536 shares of the company's stock valued at $13,605,000 after purchasing an additional 63,079 shares in the last quarter. Geode Capital Management LLC raised its stake in 10x Genomics by 2.4% during the 3rd quarter. Geode Capital Management LLC now owns 1,815,710 shares of the company's stock worth $41,009,000 after acquiring an additional 42,777 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of 10x Genomics by 355.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 355,488 shares of the company's stock valued at $8,027,000 after purchasing an additional 277,355 shares during the period. Finally, Diversified Trust Co acquired a new position in shares of 10x Genomics in the 4th quarter valued at $511,000. Hedge funds and other institutional investors own 84.68% of the company's stock.

Insider Buying and Selling at 10x Genomics

In other news, Director Alan Mateo bought 40,000 shares of the stock in a transaction on Friday, February 21st. The shares were purchased at an average price of $11.14 per share, for a total transaction of $445,600.00. Following the completion of the purchase, the director now directly owns 61,691 shares of the company's stock, valued at $687,237.74. This trade represents a 184.41 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Benjamin J. Hindson sold 4,573 shares of the stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $11.07, for a total value of $50,623.11. Following the completion of the transaction, the insider now owns 335,324 shares in the company, valued at $3,712,036.68. This represents a 1.35 % decrease in their position. The disclosure for this sale can be found here. 10.03% of the stock is currently owned by insiders.

Analysts Set New Price Targets

TXG has been the subject of several analyst reports. UBS Group cut their price target on 10x Genomics from $20.00 to $14.00 and set a "neutral" rating for the company in a research note on Thursday, February 13th. JPMorgan Chase & Co. lowered their target price on shares of 10x Genomics from $14.00 to $12.00 and set a "neutral" rating on the stock in a report on Thursday, February 13th. Citigroup reduced their price objective on shares of 10x Genomics from $20.00 to $15.00 and set a "buy" rating for the company in a research report on Tuesday, March 4th. Canaccord Genuity Group cut their target price on 10x Genomics from $20.00 to $18.00 and set a "buy" rating for the company in a research note on Thursday, February 13th. Finally, Leerink Partnrs downgraded 10x Genomics from a "strong-buy" rating to a "hold" rating in a research note on Thursday, February 13th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and seven have given a buy rating to the company's stock. Based on data from MarketBeat.com, 10x Genomics presently has a consensus rating of "Hold" and an average target price of $19.79.

10x Genomics Price Performance

TXG traded down $0.02 during trading hours on Tuesday, reaching $8.46. 705,244 shares of the stock traded hands, compared to its average volume of 3,102,337. 10x Genomics, Inc. has a fifty-two week low of $6.78 and a fifty-two week high of $29.37. The company has a market cap of $1.03 billion, a price-to-earnings ratio of -5.57 and a beta of 2.01. The firm's fifty day simple moving average is $9.40 and its two-hundred day simple moving average is $12.98.

10x Genomics (NASDAQ:TXG - Get Free Report) last issued its quarterly earnings data on Wednesday, February 12th. The company reported ($0.40) earnings per share for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.08). 10x Genomics had a negative net margin of 29.90% and a negative return on equity of 25.40%. On average, research analysts predict that 10x Genomics, Inc. will post -1.43 earnings per share for the current year.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.